1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Tolero Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Tolero Pharmaceuticals, Inc. - Product Pipeline Review - 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 35 pages

Tolero Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Tolero Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Tolero Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Tolero Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Tolero Pharmaceuticals, Inc.
- The report provides overview of Tolero Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Tolero Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Tolero Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Tolero Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Tolero Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tolero Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

Tolero Pharmaceuticals, Inc. - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Tolero Pharmaceuticals, Inc. Snapshot 5
Tolero Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Tolero Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Tolero Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Tolero Pharmaceuticals, Inc. - Pipeline Products Glance 11
Tolero Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Tolero Pharmaceuticals, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Tolero Pharmaceuticals, Inc. - Drug Profiles 13
alvocidib hydrochloride 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
HCI-1680 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
HCI-1708 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
SGI-7079 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
TP-0158 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
TP-0184 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
TP-0413 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
TP-0903 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
TP-1101 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
TP-3654 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Tolero Pharmaceuticals, Inc. - Pipeline Analysis 24
Tolero Pharmaceuticals, Inc. - Pipeline Products by Target 24
Tolero Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 25
Tolero Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 26
Tolero Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 27
Tolero Pharmaceuticals, Inc. - Recent Pipeline Updates 28
Tolero Pharmaceuticals, Inc. - Dormant Projects 31
Tolero Pharmaceuticals, Inc. - Discontinued Pipeline Products 32
Discontinued Pipeline Product Profiles 32
SGI-1776 32
Tolero Pharmaceuticals, Inc. - Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35

List of Tables
Tolero Pharmaceuticals, Inc., Key Information 5
Tolero Pharmaceuticals, Inc., Key Facts 5
Tolero Pharmaceuticals, Inc. - Pipeline by Indication, 2016 7
Tolero Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 9
Tolero Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 10
Tolero Pharmaceuticals, Inc. - Phase II, 2016 11
Tolero Pharmaceuticals, Inc. - Preclinical, 2016 12
Tolero Pharmaceuticals, Inc. - Pipeline by Target, 2016 24
Tolero Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 25
Tolero Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 26
Tolero Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 27
Tolero Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 28
Tolero Pharmaceuticals, Inc. - Dormant Developmental Projects,2016 31
Tolero Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016 32

List of Figures
Tolero Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016 7
Tolero Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 9
Tolero Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 10
Tolero Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016 24
Tolero Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 25
Tolero Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 26
Tolero Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.